Objectives: To document the response of recalcitrant warts to intralesional measles, mumps, and rubella (MMR) vaccine. Materials and Methods: This case series reports the treatment response to intralesional MMR vaccine observed in 11 patients who attended the dermatology outpatient department with recalcitrant warts of more than 1 year duration. Only the largest wart was treated in each case. The intralesional treatment was repeated at an interval of 2 weeks. Results: Nine patients (81.9%) showed complete response to treatment. One patient did not return for treatment after two sessions (9.1%). One showed incomplete treatment response (9.1%). The adverse reactions noted among the 11 patients were pain (3/11, 27.3%) and secondary bacterial infection (1/11, 9.1%). Limitations: Results are based on a case series of 11 patients. Conclusion: Intralesional MMR vaccine was found effective and safe in the management of recalcitrant warts.

Microsporum gypseum is a rare cause of kerion in infancy. Light microscopy, fluorescent microscopy and fungal culture of the infected hair aids in early and correct diagnosis. Griseofulvin is the drug of choice for ectothrix fungi. We report a case of neonatal kerion caused by M. gypseum occurring at the age of 1 month, successfully treated with griseofulvin.

Pemphigus vulgaris is an autoimmune disease affecting skin and mucous membranes, rarely found in pregnancy. It is associated with increased maternal and neonatal morbidity. Here we report the case of a woman who conceived while on treatment for active pemphigus vulgaris, and had a successful VBAC.

Immunotherapy has revolutionized the treatment of extensive and resistant warts. Promising results have extended the role of immunotherapy to other infections such as extensive molluscum contagiosum, recurrent herpes simplex infections, and cutaneous leishmaniasis, which are resistant to standard treatment. This review focuses on topical and intralesional immunotherapy in the management of cutaneous infections.